Paramedullary Disease

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-04-14
Clinical Trial Update: A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" [Phase 2]
This is a Phase 2 trial evaluating radiotherapy-induced immune priming to enhance Elranatamab in relapsed/refractory multiple myeloma with e…